Oluf Dimitri Røe
Background and activities
Appointments and research interests
My main research interests have been a combination of clinical and basic cancer research (translational), including biomarkers for early detection of cancer, predictive and prognostic biomarkers, genome-wide analysis and mechanisms of treatment resistance.
The research has been focused on mesothelioma, an asbestos-related cancer, but recently also lung and gastric cancer. I have published papers on biomarkers in serum and tissue of mesothelioma and gastric cancer in international peer-reviewed journals as Lung Cancer, PlosOne, EBioMedicine, Clinical Cancer Research and Gut. Specifically in mesothelioma my research experience includes clinical research where I initiated and completed studies on early detection of mesothelioma in pre-clinical serum in collaboration with the Cancer Registry and the Janus Biobank, with a fruitful collaboration with prof. Jeanette Creaney at the National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia. At our research department I conducted three gene expression studies at the FUGE (Functional Genomics) core facility with Affymetrix U133 Plus 2 and Illumina HumanHT-12 v3 Expression BeadChip on human mesothelioma and normal pleural samples.
The recent years a collaborative work on novel bioinformatics methods with a strong bioinformatics group lead by Prof. Ioannis Tsamardinos at the University of Crete in Greece has resulted in the HUNT Lung Cancer Model and online calculator and several new publications.
Since November 2010 a collaboration/visiting researcher/supervisor with Nanjing Medical University, China was initiated on mesothelioma, lung and gastric cancer.
As a collaborating/visiting researcher periodically at the Nanjing Medical University, I have co-authored 13 peer-reviewed papers, including in some high-impact journals as Cell Death and Disease, Gut, Clinical Cancer Research, Scientific Reports and Oncotarget (see full publication list).
There was a fruitful collaboration with the oncologists at the Nanjing Medical University Oncology Department with some publications (see publication list) and one independent collaboration with the Yuyao Peoples Hospital, Zheijiang Province, China and University of Tokyo, Japan as oneof the first papers linking mesothelioma in women to occupational asbestos exposure in China.
The prospective HUNT biobank in Levanger, Norway, is one of the largest biobanks in Scandinavia with serum and clinical data from approximately 120 000 subjects. Since May 2011 collaboration with the HUNT was initiated, aiming at tumour-specific microRNA discovery in pre-diagnostic serum. The Cancer-Biomarker-HUNT Project aims at discovery of biomarkers in serum for detection of lung cancer and mesothelioma in an early stage.
Currently, we developed a novel validated clinical risk prediction model and online calculator for lung cancer, the HUNT Lung Cancer Model which combined with GWAS and pre-diagnostic microRNA can refine the screening and diagnostic model. This project is designated EARLYSCREEN.
Since 2013- appointed as Clinical Associate Professor (20%) at the Aalborg University Hospital. Aalborg, the major and capital city in the Northern Jutland Region has hosted the only asbestos factory (Eternit) in Denmark and processed 80% of all asbestos imported to Denmark. The long term effects of the asbestos use is that the age-standardised incidence rate for men with mesothelioma in the Region of Northern Jutland in 2008-2009 is approximately 2-3-fold higher than in the other four Danish Regions, and we have newly discovered the environmental impact on the risk of mesothelioma in women as well as showing for the first time germline cancer susceptibility genes in mesothelioma, in collaboration with University of Chicago. Currently I hold a position as Clinical Associate Professor at the Department of Oncology in Aalborg, and initiated a multidisciplinary group formed to do mesothelioma research.
Since 2018- I hold a 20% Professor position at the Department of Clinical and Molecular Research, NTNU, Trondheim, Norway and Levanger Hospital.
2012 Norwegian Research Council for collaborative project with China, 310 000 NoK
2012 Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, post-doc position 60% for 5 years
2014 Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, 5,7 mill. NoK for 4 years
2015 Levanger Hospital, Nord-Trøndelag Hospital Trust, 300 000 Nok
2016 BONNIE J. ADDARIO LUNG CANCER FOUNDATION AND INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC) JOINT AWARD 2016.
2,7 mill. NoK (300 000 USD) for two years, see
2017 PhD position for Olav Toai Duc Nguyen, 6 years 50% position 2018-2024 “EARLYSCREEN; validating a novel clinical and molecular early diagnostic lung cancer screening model in HUNT and CONOR”.
2018 Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, 2.9 mill. NoK for 3 years.